JDRF

Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2024 Outlook

Retrieved on: 
Thursday, January 4, 2024

IRVINE, Calif., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced a summary of 2023 accomplishments and provided guidance for anticipated upcoming 2024 milestones.

Key Points: 
  • IRVINE, Calif., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced a summary of 2023 accomplishments and provided guidance for anticipated upcoming 2024 milestones.
  • Amended the Phase 1b trial protocol to add a second cohort, now allowing enrollment of up to 24 trial participants who are undergoing kidney transplantation.
  • Dosed first participants in Phase 2 BESTOW trial assessing tegoprubart head-to-head with tacrolimus for the prevention of rejection in kidney transplantation.
  • 2024: Dose the first islet cell transplant participant for the treatment of type 1 diabetes at the University of Chicago Transplantation Institute.

Private Equity Veteran Kelly Williams Joins Blank Rome in Houston

Retrieved on: 
Thursday, December 21, 2023

Houston, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Blank Rome LLP is pleased to announce that A. Kelly Williams has joined the firm’s Houston office as senior counsel in the Corporate, M&A, and Securities group.

Key Points: 
  • Houston, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Blank Rome LLP is pleased to announce that A. Kelly Williams has joined the firm’s Houston office as senior counsel in the Corporate, M&A, and Securities group.
  • Kelly’s addition continues Blank Rome’s strategic expansion in Texas to better serve clients who are based in or do business in the state.
  • “We are excited to welcome Kelly to the firm,” said Grant S. Palmer , Blank Rome’s Chair and Managing Partner.
  • Prior to founding Milestone, Kelly practiced law at a regional transactional and tax law firm and founded a small law firm to manage public and private business transactions.

NFL Stars Support JDRF and Champion Type 1 Diabetes Awareness through the "My Cause My Cleats" Campaign

Retrieved on: 
Saturday, December 23, 2023

NEW YORK, Dec. 22, 2023 /PRNewswire/ -- JDRF, the leading global funder of type 1 diabetes (T1D) research, is recognizing the NFL stars who showcased their creativity and a remarkable show of support as part of the highly anticipated annual "My Cause My Cleats" (MCMC) campaign.

Key Points: 
  • The unofficial start of the campaign begins on Giving Tuesday with unboxing day events showcasing the players' cleats and the stories behind them.
  • It continues through weeks 13 and 14 of the season, culminating with the players donning their cleats on game day.
  • "The NFL players who support JDRF through the My Cause My Cleats exemplify the passion and determination at the heart of the type 1 diabetes community," said Kenya Felton, JDRF Director of PR and Celebrity Engagement.
  • Their support helps to increase awareness and is significant in helping JDRF advance life-changing breakthroughs in T1D research and advocacy initiatives."

Proxygen Announces Formation of Scientific Advisory Board

Retrieved on: 
Wednesday, November 15, 2023

VIENNA, Austria, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Proxygen, a leader in the discovery and development of molecular glue degraders, today announced the formation of the company’s scientific advisory board (SAB). The newly appointed SAB, which is comprised of highly regarded thought leaders in the emerging field of protein degradation, will offer scientific expertise and guidance to Proxygen as the company works to advance its internal molecular glue degrader programs toward clinical development. In addition to its internal programs, Proxygen is also actively engaged in strategic research collaboration and license agreements with Merck & Co (known as MSD outside the U.S. and Canada), Boehringer Ingelheim and Merck KGaA designed to jointly identify and develop novel molecular glue degraders.

Key Points: 
  • SAB Comprised of Pioneers in the Field of Protein Degradation, Including Unique Expertise in Roles of Ubiquitin Biology and Translational Medicine
    VIENNA, Austria, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Proxygen, a leader in the discovery and development of molecular glue degraders, today announced the formation of the company’s scientific advisory board (SAB).
  • Schulman and Draetta to the Proxygen team as key advisors and pair them with Drs.
  • Winter and Kubicek, who co-founded the company, based on their trailblazing research at CeMM,” said Bernd Boidol, Ph.D., chief executive officer of Proxygen.
  • By streamlining and fully integrating cutting-edge genomic, proteomic, and biochemical technologies, Proxygen has successfully developed a highly versatile glue degrader discovery engine.

SAB Biotherapeutics Announces Q3 2023 Financial Results and Provides Company Updates

Retrieved on: 
Tuesday, November 14, 2023

SIOUX FALLS, S.D., Nov. 14, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing fully-human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today reported financial results for the third quarter ended October 31, 2023, and provided a company update.

Key Points: 
  • “The third quarter of 2023 was a pivotal growth point for SAB as we advance SAB-142, our T1D immunotherapy.
  • The full proceeds, when funded, are expected to fund the company through 2026 and through topline Phase 2 results.
  • Russell P. Beyer, former EVP and Chief Financial Officer, departed the Company effective October 27, 2023.
  • The decrease was primarily due to discretionary cost reduction measures and increased efficiencies as we continue to mature as a publicly traded company.

SAB Biotherapeutics Announces Completion of $67.1 Million Financing to Advance Potential Disease-Modifying Treatment for Type 1 Diabetes

Retrieved on: 
Tuesday, November 14, 2023

The proceeds from the financing will be used to fund the development of the company’s lead research program, SAB-142, a potential disease modifying treatment for T1D.

Key Points: 
  • The proceeds from the financing will be used to fund the development of the company’s lead research program, SAB-142, a potential disease modifying treatment for T1D.
  • Tranche B warrants remain outstanding, which if exercised, would result in a total of $110 million in proceeds in this financing.
  • Participating investors included Sessa Capital, BVF Partners, RTW Investments, Marshall Wace, ATW, and the JDRF T1D Fund.
  • SAB-142 directly targets multiple immune cells involved in destroying insulin-producing pancreatic beta cells to potentially preserve beta cell function.

Q2 Recognized as a Top Workplace by Austin American-Statesman

Retrieved on: 
Monday, November 13, 2023

Q2 Holdings, Inc. (NYSE:QTWO), a leading provider of digital transformation solutions for banking and lending, today announced it was recognized as a Top Workplaces 2023 award winner by Austin American-Statesman, marking its 13th consecutive year on the list.

Key Points: 
  • Q2 Holdings, Inc. (NYSE:QTWO), a leading provider of digital transformation solutions for banking and lending, today announced it was recognized as a Top Workplaces 2023 award winner by Austin American-Statesman, marking its 13th consecutive year on the list.
  • The award is based solely on employee feedback gathered through a third-party survey administered by employee engagement technology partner Energage LLC .
  • “At Q2, our mission is to build strong and diverse communities by strengthening their financial institutions,” said Q2 CEO Matt Flake.
  • In partnership with Austin FC , Q2 helps to promote diversity, equity and inclusion in the Central Texas community through the Q-mmunity Gives grant program and Austin FC Dream Starter Competition.

JDRF Moves the Type 1 Diabetes Community "Forward" in Honor of World Diabetes Day and National Diabetes Awareness Month

Retrieved on: 
Tuesday, November 14, 2023

NEW YORK, Nov. 14, 2023 /PRNewswire/ -- JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization, recognizes this year's World Diabetes Day and National Diabetes Awareness Month by celebrating the progress made and the work to come with its annual "FORWARD" campaign.

Key Points: 
  • The annual campaign recognizes exciting breakthroughs in type 1 diabetes research and care while acknowledging the perseverance of those living with the disease.
  • NEW YORK, Nov. 14, 2023 /PRNewswire/ -- JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization, recognizes this year's World Diabetes Day and National Diabetes Awareness Month by celebrating the progress made and the work to come with its annual "FORWARD" campaign.
  • JDRF will also host "T1D Across the Globe," the final virtual TypeOneNation Summit for 2023.
  • To learn more about the JDRF "FORWARD" campaign and other initiatives, please visit https://www.jdrf.org/NDAM/ .

Panbela Announces Publication of Preclinical and Clinical Data Titled: Inhibition of Polyamine Biosynthesis Preserves β Cell Function in Type 1 Diabetes

Retrieved on: 
Thursday, November 2, 2023

A Phase 1 clinical study showed that DFMO treatment may provide metabolic benefits to preserve β cell function and health in T1D.

Key Points: 
  • A Phase 1 clinical study showed that DFMO treatment may provide metabolic benefits to preserve β cell function and health in T1D.
  • Data published in the journal Cell Reports Medicine investigated the mechanism of polyamines and polyamine inhibition by CPP-1X on β cell stress that plays a role in the onset of type 1 diabetes in in vitro and ex vivo models.
  • Results showed that DFMO treatment may preserve β cell function, reflected by C-peptide levels in patients with T1D through the modulation of urinary polyamines, in particular putrescine.
  • Results from these studies suggest that CPP-1X is a safe, oral treatment option that may improve β cell function and/or survival in recent onset T1D.

Insulet Spotlights Diabetes Awareness on World Diabetes Day and Throughout November

Retrieved on: 
Wednesday, November 1, 2023

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced a series of initiatives in recognition of National Diabetes Awareness Month and World Diabetes Day.

Key Points: 
  • Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced a series of initiatives in recognition of National Diabetes Awareness Month and World Diabetes Day.
  • “World Diabetes Day may be just one day on the calendar, but for those living with diabetes, every day requires resilience and strength.
  • #JustMyType Social Media Campaign – Insulet is encouraging the global diabetes community to create awareness and increase representation of people with diabetes through its #JustMyType campaign.
  • To learn more about diabetes or to access helpful resources for living with diabetes, visit the American Diabetes Association , JDRF , and the International Diabetes Federation.